Tabimorelin

Orally active GH secretagogue acting on ghrelin receptors. Earlier-generation GHSR agonist developed before MK-677 became the dominant oral GH secretagogue in community use.

0 anonymous reports

Also known as:

nn703oral ghrpghrp oral

browse topics:

Peptides for Muscle Growth

community guides:

Growth Hormone PeptidesBest Peptide StacksReconstituting PeptidesInjecting Peptides

No reports found.

Community Q&A

Is tabimorelin still used?
Community accounts for tabimorelin are sparse — it has been superseded by MK-677 (ibutamoren) as the dominant oral GH secretagogue. Development was discontinued commercially before MK-677 established its community presence. Accounts referencing tabimorelin appear in historical or comparative discussions about oral secretagogues rather than in active use protocols. Most community members encountering tabimorelin in research contexts conclude that MK-677 is the more accessible and community-tested alternative.
How does tabimorelin compare to MK-677?
Community accounts describe tabimorelin as producing similar GH and IGF-1 elevation through the same ghrelin receptor mechanism. MK-677's advantage in accounts: significantly more community data, better sourcing, and an established dosing consensus. The primary reason tabimorelin doesn't feature in community protocols is practical rather than efficacy-related — it is difficult to source and has no active supply chain compared to MK-677.